Aarden Pharmaceuticals

About:

Aarden Pharmaceuticals develops drugs targeting protein tyrosine phosphatases that catalyze the removal of phosphate groups.

Website: http://aardenpharma.com

Top Investors: IU Ventures

Description:

Aarden Pharmaceuticals is a small molecule drug discovery and development company. The company’s novel technology is a chemistry breakthrough that will enable it to make drugs against a previously un-druggable set of intracellular phosphatase (PTP) disease targets. The technology was developed in the laboratory of Dr. Zhong-Yin Zhang, Robert A. Harris Professor and chairman of biochemistry and molecular biology at the Indiana University School of Medicine. Zhang is an internationally recognized expert in the field of protein tyrosine phosphatases (PTPs). Aarden’s first programs are focused on infectious disease, cancer, and metabolic and autoimmune conditions.

Total Funding Amount:

$500000

Headquarters Location:

Indianapolis, Indiana, United States

Founded Date:

2008-01-01

Contact Email:

gnoonan(AT)aardenpharma.com

Founders:

Christopher LeMasters, Thomas M. Estok, Zhong-Yin Zhang

Number of Employees:

1-10

Last Funding Date:

2011-01-03

IPO Status:

Private

Industries:

© 2025 bioDAO.ai